Superselective intraarterial cerebral infusion of bevacizumab: A revival of interventional neuro-oncology for malignant glioma

Journal of Experimental Therapeutics and Oncology

Volumn 8, Issue 2, 2009, Pages 145-150

  Riina, Howard A ^a   Fraser, Justin F ^a   Fralin, Sherese ^a   Knopman, Jared ^a   Scheff, Ronald J ^a   Boockvar, John A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Bevacizumab; Brain tumors; Glioma; Intra arterial injection

Indexed keywords

BEVACIZUMAB; IRINOTECAN; MANNITOL; TEMOZOLOMIDE;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CANCER SURVIVAL; CLINICAL TRIAL; DRUG INFUSION; DRUG SAFETY; GENERAL CONDITION IMPROVEMENT; GLIOBLASTOMA; HAND PARESTHESIA; HUMAN; MALE; MEMORY DISORDER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SEIZURE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; CEREBRAL ANGIOGRAPHY; GLIOBLASTOMA; HUMANS; INFUSIONS, INTRA-ARTERIAL; MAGNETIC RESONANCE IMAGING; MALE; MANNITOL; MICROINJECTIONS;

EID: 74049102130     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Sathornsumetee S and Rich JN: Antiangiogenic therapy in malignant glioma: promise and challenge. Curr Pharm Des 2007, 13(35):3545-3558.
2. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH and Friedman HS: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007, 13(4): 1253-1259.
3. Pope WB, Lai A, Nghiemphu P, Mischel P and Cloughesy TF: MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006, 66(8): 1258-1260.
4. Nghiemphu PL, Green RM, Pope WB, Lai A and Cloughesy TF: Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol 2008, 10(3):355-360.
5. Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M and Cloughesy T: Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 2008, 71(5):1372-1380.
6. Ananthnarayan S, Bahng J, Roring J, Nghiemphu P, Lai A, Cloughesy T and Pope WB: Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol 2008, 88(3):339-347.
7. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME and Cloughesy T: Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007, 25(30):4714-4721.
8. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M and Cloughesy T: Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. J Clin Oncol 2009.
9. Gobin YP, Cloughesy TF, Chow KL, Duckwiler GR, Sayre JW, Milanese K and Vinuela F: Intraarterial chemotherapy for brain tumors by using a spatial dose fractionation algorithm and pulsatile delivery. Radiology 2001, 218(3):724-732.
10. Namba H, Kobayashi S, Iwadate Y, Saegusa T, Sato A, Watanabe Y and Sueyoshi K: Assessment of the brain areas perfused by superselective intra-arterial chemotherapy using single photon emission computed tomography with technetium-99mhexamethyl-propyleneamine oxime - technical note. Neurol Med Chir (Tokyo) 1994, 34(12):832-835.
11. Hochberg FH, Pruitt AA, Beck DO, DeBrun G and Davis K: The rationale and methodology for intra-arterial chemotherapy with BCNU as treatment for glioblastoma. J Neurosurg 1985, 63(6):876-880.
12. Imbesi F, Marchioni E, Benericetti E, Zappoli F, Galli A, Corato M and Ceroni M: A randomized phase III study: comparison between intravenous and intraarterial ACNU administration in newly diagnosed primary glioblastomas. Anticancer Res 2006, 26(1B):553-558.
13. Shapiro WR, Green SB, Burger PC, Selker RG, VanGilder JC, Robertson JT, Mealey J, Jr., Ransohff J and Mahaley MS, Jr.: A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 1992, 76(5):772-781.
14. West CR, Avellanosa AM, Barua NR, Patel A and Hong CI: Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and systemic chemotherapy for malignant gliomas: a follow-up study. Neurosurgery 1983, 13(4):420-426.
15. Kim JH, Yoon HK, Sung KB, Ko GY, Gwon DI, Shin JH and Song HY: Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer 2008, 113(7):1614-1622.
16. Neuwelt EA, Abbott NJ, Drewes L, Smith QR, Couraud PO, Chiocca EA, Audus KL, Greig NH and Doolittle ND: Cerebrovascular Biology and the various neural barriers: challenges and future directions. Neurosurgery 1999, 44(3): 604-608; discussion 608-609.
17. Neuwelt EA, Barnett PA, McCormick CI, Frenkel EP and Minna JD: Osmotic blood-brain barrier modification: monoclonal antibody, albumin, and methotrexate delivery to cerebrospinal fluid and brain. Neurosurgery 1985, 17(3):419-423.
18. Neuwelt EA, Gilmer-Knight K, Lacy C, Nicholson HS, Kraemer DF, Doolittle ND, Hornig GW and Muldoon LL: Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption. Pediatr Blood Cancer 2006, 47(2):174-182.
19. Neuwelt EA, Howieson J, Frenkel EP, Specht HD, Weigel R, Buchan CG and Hill SA: Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery 1986, 19(4):573-582.
20. Neuwelt EA, Minna J, Frenkel E, Barnett PA and McCormick CI: Osmotic blood-brain barrier opening to IgM monoclonal antibody in the rat. Am J Physiol 1986, 250(5 Pt 2):R875-883.
21. Neuwelt EA, Specht HD and Hill SA: Permeability of human brain tumor to 99mTc-gluco-heptonate and 99mTc-albumin. Implications for monoclonal antibody therapy. J Neurosurg 1986, 65(2):194-198.
22. Neuwelt EA, Barnett PA, Hellstrom KE, Hellstrom I, McCormick CI and Ramsey FL: Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts. J Nucl Med 1994, 35(11):1831-1841.
23. Neuwelt EA and Dahlborg SA: Chemotherapy administered in conjunction with osmotic blood-brain barrier modification in patients with brain metastases. J Neurooncol 1987, 4(3): 195-207.
24. Neuwelt EA, Mickey B and Lewy AJ: The importance of melatonin and tumor markers in pineal tumors. J Neural Transm Suppl 1986, 21:397-413.
25. Hall WA, Doolittle ND, Daman M, Bruns PK, Muldoon L, Fortin D and Neuwelt EA: Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas. J Neurooncol 2006, 77(3):279-284.
26. Fortin D, Desjardins A, Benko A, Niyonsega T and Boudrias M: Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. Cancer 2005, 103(12):2606-2615.